Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Launches New Response Body To Tackle Future Health Emergencies

HERA To Boost New Vaccines & Therapeutic Development, Clinical Trials & Manufacturing

Executive Summary

The European Commission has dismissed concerns about the operation of its new emergency response body, saying it will ensure the EU is well prepared for tackling future pandemics and other threats. HERA will complement, not duplicate, work conducted by existing agencies such as the European Medicines Agency, delegates heard at this week’s European Health Forum Gastein virtual conference.

You may also be interested in...



EU’s New Health Crisis Response Body ‘Won’t Duplicate’ Work Of EMA And ECDC

The directors of two key EU agencies outlined how they would work with the new HERA, and how they see their new roles under draft legislation aimed at strengthening their responses to health crises, at the recent European Health Forum Gastein conference. The European Medicines Agency also flagged up the potential role of real-world evidence in monitoring the safety and effectiveness of COVID-19 vaccines.

EU Wants Pharma To Offer ‘Ever-Warm’ Vaccine & Drug Production Capacity

As part of its efforts to bolster Europe’s readiness for health emergencies, the European Commission wants to make sure that additional production capacity is available at short notice.

European Commission Steps Further Towards ‘Ambitious’ Pharma Legislation Reform

The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.

Related Content

Topics

UsernamePublicRestriction

Register

PS145020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel